Fintech PR
AMSC ASA: Agreement on participation in Solstad Offshore’s refinancing transaction
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
LYSAKER, Norway, Oct. 23, 2023 /PRNewswire/ — Reference is made to the stock exchange announcement by Solstad Offshore ASA (“SOFF”) today that Solstad Shipholding AS (“Solstad”) has reached an agreement with Aker ASA (via its wholly owned subsidiary Aker Capital AS, hereinafter “Aker”), AMSC ASA (“AMSC”), DNB Bank ASA (“DNB”) and Export Finance Norway (“Eksfin”) for an overall refinancing solution which will create a robust industrial platform going forward (the “Refinancing”).
AMSC will participate in the Refinancing through contributing 100% of the shares in Offshore Leasing I, which owns the CSV Normand Maximus with corresponding bareboat contract and secured bank debt, in kind, in return for new common shares in the parent company of the new corporate structure (“Solstad NewCo”) which will be established in connection with the Refinancing.
The Refinancing is based on a pre-money valuation of Solstad NewCo of NOK 1,500 million. AMSC’s contribution to Solstad NewCo is valued at NOK 1,000 million, based on an enterprise value of Offshore Leasing I of USD 177.5 million per 31 December 2023, with assumed outstanding debt of USD 86.5 million. Following completion of the transaction, AMSC expects to hold approximately 18.2% of the shares and votes in Solstad NewCo.
The subscription price per Solstad NewCo share in the transaction will be similar to the subscription price per share in the NOK 3.0 billion private placements of shares in Solstad NewCo directed towards Aker and existing Solstad shareholders, provided that if currency fluctuations result in the contribution being valued lower than NOK 1,000 million at closing, the subscription price will be reduced in so far as necessary to issue the agreed number of shares on the basis of the agreed valuation of NOK 1,000 million, as further described in the stock exchange announcement from SOFF.
In connection with the transaction, AMSC, Aker and Solstad will enter into a shareholders’ agreement which shall give each of AMSC and Solstad the right to appoint one board member and one observer to the board of directors of Solstad NewCo. Aker shall have the right to appoint a majority of the board members of Solstad NewCo. The shareholders’ agreement contains other customary provisions, including an intent to procure that the shares in Solstad NewCo are listed on a regulated market within 12 months from closing of the transaction.
Completion of the Refinancing, including AMSC’s contribution of the shares in Offshore Leasing I in exchange for shares in Solstad NewCo, is subject to customary closing conditions. Completion of the Refinancing is expected to take place around year-end 2023.
Pål Lothe Magnussen, CEO of AMSC, commented that “We are excited to become a significant shareholder in Solstad NewCo, and continue the cooperation with Solstad that started last year through the acquisition and bareboat lease of the CSV Normand Maximus. We believe Solstad NewCo is an attractrive investment for AMSC as it maintains our exposure to the offshore industry while diversifying from one vessel to a broader fleet of high quality CSV and AHTS vessels. Solstad NewCo is well positioned in a strong and improving offshore market, and will following the Refinancing be financially healthy and have a clear ambition to initiate quarterly dividend payments in 2024.”
Pro-forma for this transaction, AMSC’s balance sheet will include about USD 60 million of cash in addition to the shares in Solstad NewCo and no external debt. AMSC’s ambition is to continue to invest in the maritime space, seek attractive risk/reward opportunities and intend to continue paying attractive quarterly dividends to its shareholders. Dividend guidance for the next quarterly dividend is $0.05 per share.
For further information and the complete details about the refinancing transaction and terms, please refer to Solstad Offshore ASA’s announcement from today available at: https://newsweb.oslobors.no/
AMSC ASA Contacts:
Pål Lothe Magnussen, +47 90 54 59 59, [email protected]
This information is considered to be inside information pursuant to the EU Market Abuse Regulation article 7 and is subject to the disclosure requirements pursuant to MAR article 17 and Section 5-12 the Norwegian Securities Trading Act.
This stock exchange announcement was published by Morten Bakke, CFO, at 07:50, October 23, 2023.
View original content:https://www.prnewswire.co.uk/news-releases/amsc-asa-agreement-on-participation-in-solstad-offshores-refinancing-transaction-301964132.html
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News5 days ago
Trina Storage Recognized as Tier 1 Energy Storage Manufacturer by BNEF for Second Consecutive Quarter
-
Latest News4 days ago
Bank of Spain grants Amadeus’ Outpayce EMI licence
-
Latest News5 days agoGenome and Chilli Partners join forces to revolutionize iGaming affiliate payouts
-
Latest News4 days ago
EQT to acquire WSO2, a leading global provider of digital transformation technologies
-
Latest News4 days ago
Newmark Reports First Quarter 2024 Financial Results
-
Latest News5 days ago
Lunar Poised for Nationwide Rollout in Sweden After Securing €24.1 Million in Funding
-
Latest News4 days ago
REALTY ONE GROUP CELEBRATES 19TH ANNIVERSARY WITH GLOBAL ‘ONE DAY’ OF VOLUNTEERING & GIVING BACK
-
Latest News4 days ago
BIZCLIK MEDIA LAUNCHES MAY EDITION OF FINTECH MAGAZINE
